nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—Emotional disorder—Varenicline—nicotine dependence	0.0428	0.0585	CcSEcCtD
Irbesartan—Abnormal faeces—Varenicline—nicotine dependence	0.0327	0.0447	CcSEcCtD
Irbesartan—Joint stiffness—Varenicline—nicotine dependence	0.0309	0.0423	CcSEcCtD
Irbesartan—Respiratory tract congestion—Varenicline—nicotine dependence	0.0256	0.035	CcSEcCtD
Irbesartan—Musculoskeletal chest pain—Varenicline—nicotine dependence	0.0241	0.033	CcSEcCtD
Irbesartan—Myositis—Varenicline—nicotine dependence	0.019	0.0261	CcSEcCtD
Irbesartan—Transient ischaemic attack—Varenicline—nicotine dependence	0.0185	0.0253	CcSEcCtD
Irbesartan—Sleep disturbance—Varenicline—nicotine dependence	0.0167	0.0228	CcSEcCtD
Irbesartan—Sexual dysfunction—Varenicline—nicotine dependence	0.0167	0.0228	CcSEcCtD
Irbesartan—CYP2C8—CYP2E1 reactions—CYP2A7—nicotine dependence	0.012	0.0501	CbGpPWpGaD
Irbesartan—Glycosuria—Varenicline—nicotine dependence	0.0115	0.0158	CcSEcCtD
Irbesartan—Tenderness—Varenicline—nicotine dependence	0.0107	0.0146	CcSEcCtD
Irbesartan—Gastrooesophageal reflux disease—Varenicline—nicotine dependence	0.0103	0.0141	CcSEcCtD
Irbesartan—CYP2D6—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00985	0.0411	CbGpPWpGaD
Irbesartan—CYP2C9—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00977	0.0407	CbGpPWpGaD
Irbesartan—Coordination abnormal—Varenicline—nicotine dependence	0.00951	0.013	CcSEcCtD
Irbesartan—Musculoskeletal pain—Varenicline—nicotine dependence	0.00945	0.0129	CcSEcCtD
Irbesartan—Blood pressure increased—Varenicline—nicotine dependence	0.00934	0.0128	CcSEcCtD
Irbesartan—Hyperkalaemia—Varenicline—nicotine dependence	0.00918	0.0126	CcSEcCtD
Irbesartan—Oesophagitis—Varenicline—nicotine dependence	0.00853	0.0117	CcSEcCtD
Irbesartan—Sleep disorder—Varenicline—nicotine dependence	0.00783	0.0107	CcSEcCtD
Irbesartan—Diabetes mellitus—Varenicline—nicotine dependence	0.00779	0.0107	CcSEcCtD
Irbesartan—CYP2D6—Fatty acids—CYP2A7—nicotine dependence	0.00769	0.0321	CbGpPWpGaD
Irbesartan—CYP2C8—Xenobiotics—CYP2A7—nicotine dependence	0.00744	0.031	CbGpPWpGaD
Irbesartan—Injury—Varenicline—nicotine dependence	0.00738	0.0101	CcSEcCtD
Irbesartan—Hot flush—Varenicline—nicotine dependence	0.00725	0.00992	CcSEcCtD
Irbesartan—Increased appetite—Varenicline—nicotine dependence	0.00722	0.00987	CcSEcCtD
Irbesartan—Menopausal symptoms—Varenicline—nicotine dependence	0.00718	0.00983	CcSEcCtD
Irbesartan—Visual disturbance—Varenicline—nicotine dependence	0.00715	0.00979	CcSEcCtD
Irbesartan—Arthritis—Varenicline—nicotine dependence	0.00697	0.00954	CcSEcCtD
Irbesartan—Cerebrovascular accident—Varenicline—nicotine dependence	0.00692	0.00947	CcSEcCtD
Irbesartan—Affect lability—Varenicline—nicotine dependence	0.00667	0.00913	CcSEcCtD
Irbesartan—EDNRA—Peptide GPCRs—OPRM1—nicotine dependence	0.00646	0.027	CbGpPWpGaD
Irbesartan—Mood swings—Varenicline—nicotine dependence	0.00642	0.00879	CcSEcCtD
Irbesartan—Liver function test abnormal—Varenicline—nicotine dependence	0.00626	0.00856	CcSEcCtD
Irbesartan—Abdominal pain upper—Varenicline—nicotine dependence	0.00619	0.00847	CcSEcCtD
Irbesartan—Hypokalaemia—Varenicline—nicotine dependence	0.00617	0.00844	CcSEcCtD
Irbesartan—Breast disorder—Varenicline—nicotine dependence	0.00613	0.00838	CcSEcCtD
Irbesartan—CYP2D6—Xenobiotics—CYP2A7—nicotine dependence	0.00611	0.0255	CbGpPWpGaD
Irbesartan—Cramp muscle—Varenicline—nicotine dependence	0.0061	0.00835	CcSEcCtD
Irbesartan—Nasopharyngitis—Varenicline—nicotine dependence	0.00606	0.00829	CcSEcCtD
Irbesartan—CYP2C9—Xenobiotics—CYP2A7—nicotine dependence	0.00605	0.0252	CbGpPWpGaD
Irbesartan—Abdominal distension—Varenicline—nicotine dependence	0.0059	0.00807	CcSEcCtD
Irbesartan—Asthma—Varenicline—nicotine dependence	0.00586	0.00802	CcSEcCtD
Irbesartan—Dysphagia—Varenicline—nicotine dependence	0.00586	0.00802	CcSEcCtD
Irbesartan—Angina pectoris—Varenicline—nicotine dependence	0.00571	0.00781	CcSEcCtD
Irbesartan—JUN—RAC1 signaling pathway—WASF2—nicotine dependence	0.00565	0.0236	CbGpPWpGaD
Irbesartan—JUN—RAC1 signaling pathway—WASF1—nicotine dependence	0.00542	0.0226	CbGpPWpGaD
Irbesartan—Photosensitivity reaction—Varenicline—nicotine dependence	0.00535	0.00732	CcSEcCtD
Irbesartan—Weight increased—Varenicline—nicotine dependence	0.00533	0.0073	CcSEcCtD
Irbesartan—Hyperglycaemia—Varenicline—nicotine dependence	0.00529	0.00723	CcSEcCtD
Irbesartan—CYP1A2—Xenobiotics—CYP2A7—nicotine dependence	0.00517	0.0216	CbGpPWpGaD
Irbesartan—Acute coronary syndrome—Varenicline—nicotine dependence	0.00515	0.00705	CcSEcCtD
Irbesartan—Myocardial infarction—Varenicline—nicotine dependence	0.00512	0.00701	CcSEcCtD
Irbesartan—Conjunctivitis—Varenicline—nicotine dependence	0.00508	0.00695	CcSEcCtD
Irbesartan—AGTR1—Peptide GPCRs—OPRM1—nicotine dependence	0.00507	0.0212	CbGpPWpGaD
Irbesartan—Hepatobiliary disease—Varenicline—nicotine dependence	0.00494	0.00676	CcSEcCtD
Irbesartan—Epistaxis—Varenicline—nicotine dependence	0.00493	0.00674	CcSEcCtD
Irbesartan—JUN—cardiovascular system—nicotine dependence	0.00491	0.167	CbGeAlD
Irbesartan—Bradycardia—Varenicline—nicotine dependence	0.00477	0.00653	CcSEcCtD
Irbesartan—Hypoaesthesia—Varenicline—nicotine dependence	0.00467	0.00638	CcSEcCtD
Irbesartan—Urinary tract disorder—Varenicline—nicotine dependence	0.00463	0.00634	CcSEcCtD
Irbesartan—Oedema peripheral—Varenicline—nicotine dependence	0.00462	0.00632	CcSEcCtD
Irbesartan—Connective tissue disorder—Varenicline—nicotine dependence	0.00461	0.00631	CcSEcCtD
Irbesartan—Urethral disorder—Varenicline—nicotine dependence	0.0046	0.00629	CcSEcCtD
Irbesartan—Visual impairment—Varenicline—nicotine dependence	0.00452	0.00618	CcSEcCtD
Irbesartan—Tinnitus—Varenicline—nicotine dependence	0.00437	0.00598	CcSEcCtD
Irbesartan—Cardiac disorder—Varenicline—nicotine dependence	0.00435	0.00596	CcSEcCtD
Irbesartan—Angiopathy—Varenicline—nicotine dependence	0.00425	0.00582	CcSEcCtD
Irbesartan—Immune system disorder—Varenicline—nicotine dependence	0.00424	0.0058	CcSEcCtD
Irbesartan—Mediastinal disorder—Varenicline—nicotine dependence	0.00423	0.00578	CcSEcCtD
Irbesartan—Chills—Varenicline—nicotine dependence	0.00421	0.00576	CcSEcCtD
Irbesartan—EDNRA—midbrain—nicotine dependence	0.0042	0.143	CbGeAlD
Irbesartan—Arrhythmia—Varenicline—nicotine dependence	0.00419	0.00573	CcSEcCtD
Irbesartan—Malnutrition—Varenicline—nicotine dependence	0.00408	0.00559	CcSEcCtD
Irbesartan—Erythema—Varenicline—nicotine dependence	0.00408	0.00559	CcSEcCtD
Irbesartan—Flatulence—Varenicline—nicotine dependence	0.00402	0.0055	CcSEcCtD
Irbesartan—Dysgeusia—Varenicline—nicotine dependence	0.004	0.00547	CcSEcCtD
Irbesartan—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.00399	0.0167	CbGpPWpGaD
Irbesartan—Muscle spasms—Varenicline—nicotine dependence	0.00392	0.00537	CcSEcCtD
Irbesartan—UGT1A3—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00388	0.0162	CbGpPWpGaD
Irbesartan—PTGS1—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00388	0.0162	CbGpPWpGaD
Irbesartan—Vision blurred—Varenicline—nicotine dependence	0.00385	0.00526	CcSEcCtD
Irbesartan—JUN—midbrain—nicotine dependence	0.00383	0.131	CbGeAlD
Irbesartan—Tremor—Varenicline—nicotine dependence	0.00382	0.00523	CcSEcCtD
Irbesartan—Ill-defined disorder—Varenicline—nicotine dependence	0.00379	0.00518	CcSEcCtD
Irbesartan—Anaemia—Varenicline—nicotine dependence	0.00377	0.00516	CcSEcCtD
Irbesartan—Agitation—Varenicline—nicotine dependence	0.00375	0.00513	CcSEcCtD
Irbesartan—Angioedema—Varenicline—nicotine dependence	0.00373	0.0051	CcSEcCtD
Irbesartan—AGTR1—cardiovascular system—nicotine dependence	0.0037	0.126	CbGeAlD
Irbesartan—EDNRA—GPCR ligand binding—TAS2R16—nicotine dependence	0.00368	0.0154	CbGpPWpGaD
Irbesartan—Malaise—Varenicline—nicotine dependence	0.00368	0.00504	CcSEcCtD
Irbesartan—Vertigo—Varenicline—nicotine dependence	0.00367	0.00502	CcSEcCtD
Irbesartan—Syncope—Varenicline—nicotine dependence	0.00366	0.00501	CcSEcCtD
Irbesartan—UGT1A3—Biological oxidations—CYP2A7—nicotine dependence	0.00366	0.0152	CbGpPWpGaD
Irbesartan—UGT1A3—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00361	0.015	CbGpPWpGaD
Irbesartan—Loss of consciousness—Varenicline—nicotine dependence	0.00359	0.00491	CcSEcCtD
Irbesartan—Cough—Varenicline—nicotine dependence	0.00356	0.00487	CcSEcCtD
Irbesartan—Hypertension—Varenicline—nicotine dependence	0.00352	0.00482	CcSEcCtD
Irbesartan—Chest pain—Varenicline—nicotine dependence	0.00348	0.00476	CcSEcCtD
Irbesartan—Arthralgia—Varenicline—nicotine dependence	0.00348	0.00476	CcSEcCtD
Irbesartan—Myalgia—Varenicline—nicotine dependence	0.00348	0.00476	CcSEcCtD
Irbesartan—Anxiety—Varenicline—nicotine dependence	0.00346	0.00474	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.00345	0.00472	CcSEcCtD
Irbesartan—Discomfort—Varenicline—nicotine dependence	0.00343	0.0047	CcSEcCtD
Irbesartan—Dry mouth—Varenicline—nicotine dependence	0.0034	0.00465	CcSEcCtD
Irbesartan—Oedema—Varenicline—nicotine dependence	0.00333	0.00456	CcSEcCtD
Irbesartan—JUN—ErbB1 downstream signaling—WASF2—nicotine dependence	0.00332	0.0138	CbGpPWpGaD
Irbesartan—Infection—Varenicline—nicotine dependence	0.00331	0.00453	CcSEcCtD
Irbesartan—Shock—Varenicline—nicotine dependence	0.00328	0.00449	CcSEcCtD
Irbesartan—Nervous system disorder—Varenicline—nicotine dependence	0.00327	0.00447	CcSEcCtD
Irbesartan—Thrombocytopenia—Varenicline—nicotine dependence	0.00326	0.00446	CcSEcCtD
Irbesartan—Tachycardia—Varenicline—nicotine dependence	0.00325	0.00445	CcSEcCtD
Irbesartan—JUN—TCR Signaling Pathway—OPRM1—nicotine dependence	0.00324	0.0135	CbGpPWpGaD
Irbesartan—Skin disorder—Varenicline—nicotine dependence	0.00324	0.00443	CcSEcCtD
Irbesartan—Hyperhidrosis—Varenicline—nicotine dependence	0.00322	0.00441	CcSEcCtD
Irbesartan—Anorexia—Varenicline—nicotine dependence	0.00318	0.00435	CcSEcCtD
Irbesartan—Hypotension—Varenicline—nicotine dependence	0.00311	0.00426	CcSEcCtD
Irbesartan—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00309	0.0129	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.00306	0.0128	CbGpPWpGaD
Irbesartan—CYP2C8—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00305	0.0127	CbGpPWpGaD
Irbesartan—EDNRA—Peptide ligand-binding receptors—OPRM1—nicotine dependence	0.00304	0.0127	CbGpPWpGaD
Irbesartan—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.00304	0.00415	CcSEcCtD
Irbesartan—Dyspnoea—Varenicline—nicotine dependence	0.00297	0.00406	CcSEcCtD
Irbesartan—Somnolence—Varenicline—nicotine dependence	0.00296	0.00405	CcSEcCtD
Irbesartan—Dyspepsia—Varenicline—nicotine dependence	0.00293	0.00401	CcSEcCtD
Irbesartan—Decreased appetite—Varenicline—nicotine dependence	0.0029	0.00396	CcSEcCtD
Irbesartan—AGTR1—GPCR ligand binding—TAS2R16—nicotine dependence	0.00289	0.0121	CbGpPWpGaD
Irbesartan—JUN—PDGFR-beta signaling pathway—WASF2—nicotine dependence	0.00289	0.012	CbGpPWpGaD
Irbesartan—Gastrointestinal disorder—Varenicline—nicotine dependence	0.00288	0.00394	CcSEcCtD
Irbesartan—Fatigue—Varenicline—nicotine dependence	0.00287	0.00393	CcSEcCtD
Irbesartan—Constipation—Varenicline—nicotine dependence	0.00285	0.0039	CcSEcCtD
Irbesartan—Pain—Varenicline—nicotine dependence	0.00285	0.0039	CcSEcCtD
Irbesartan—Feeling abnormal—Varenicline—nicotine dependence	0.00275	0.00376	CcSEcCtD
Irbesartan—Gastrointestinal pain—Varenicline—nicotine dependence	0.00272	0.00373	CcSEcCtD
Irbesartan—Urticaria—Varenicline—nicotine dependence	0.00265	0.00362	CcSEcCtD
Irbesartan—EDNRA—brain—nicotine dependence	0.00264	0.0899	CbGeAlD
Irbesartan—Body temperature increased—Varenicline—nicotine dependence	0.00263	0.0036	CcSEcCtD
Irbesartan—Abdominal pain—Varenicline—nicotine dependence	0.00263	0.0036	CcSEcCtD
Irbesartan—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00254	0.0106	CbGpPWpGaD
Irbesartan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00251	0.0105	CbGpPWpGaD
Irbesartan—CYP2C8—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.0025	0.0104	CbGpPWpGaD
Irbesartan—CYP2D6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.0025	0.0104	CbGpPWpGaD
Irbesartan—CYP2C9—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00248	0.0103	CbGpPWpGaD
Irbesartan—Hypersensitivity—Varenicline—nicotine dependence	0.00245	0.00336	CcSEcCtD
Irbesartan—JUN—brain—nicotine dependence	0.00241	0.0821	CbGeAlD
Irbesartan—Asthenia—Varenicline—nicotine dependence	0.00239	0.00327	CcSEcCtD
Irbesartan—AGTR1—Peptide ligand-binding receptors—OPRM1—nicotine dependence	0.00239	0.00995	CbGpPWpGaD
Irbesartan—EDNRA—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00238	0.00993	CbGpPWpGaD
Irbesartan—Pruritus—Varenicline—nicotine dependence	0.00236	0.00323	CcSEcCtD
Irbesartan—Diarrhoea—Varenicline—nicotine dependence	0.00228	0.00312	CcSEcCtD
Irbesartan—Dizziness—Varenicline—nicotine dependence	0.0022	0.00301	CcSEcCtD
Irbesartan—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00215	0.00896	CbGpPWpGaD
Irbesartan—CYP1A2—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00212	0.00884	CbGpPWpGaD
Irbesartan—Vomiting—Varenicline—nicotine dependence	0.00212	0.0029	CcSEcCtD
Irbesartan—Rash—Varenicline—nicotine dependence	0.0021	0.00287	CcSEcCtD
Irbesartan—Dermatitis—Varenicline—nicotine dependence	0.0021	0.00287	CcSEcCtD
Irbesartan—Headache—Varenicline—nicotine dependence	0.00209	0.00286	CcSEcCtD
Irbesartan—EDNRA—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00208	0.00868	CbGpPWpGaD
Irbesartan—PTGS1—Biological oxidations—CYP2A7—nicotine dependence	0.00206	0.00859	CbGpPWpGaD
Irbesartan—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00206	0.00857	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00204	0.00851	CbGpPWpGaD
Irbesartan—EDNRA—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00204	0.0085	CbGpPWpGaD
Irbesartan—CYP2C9—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00204	0.0085	CbGpPWpGaD
Irbesartan—Nausea—Varenicline—nicotine dependence	0.00198	0.00271	CcSEcCtD
Irbesartan—EDNRA—Signaling by GPCR—TAS2R16—nicotine dependence	0.00189	0.00788	CbGpPWpGaD
Irbesartan—AGTR1—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00187	0.00779	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.00185	0.00773	CbGpPWpGaD
Irbesartan—AGTR1—brain—nicotine dependence	0.00181	0.0618	CbGeAlD
Irbesartan—CYP2C9—cardiovascular system—nicotine dependence	0.00178	0.0606	CbGeAlD
Irbesartan—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00174	0.00726	CbGpPWpGaD
Irbesartan—EDNRA—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00172	0.00718	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—CHRNB2—nicotine dependence	0.00167	0.00695	CbGpPWpGaD
Irbesartan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00166	0.00691	CbGpPWpGaD
Irbesartan—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00164	0.00682	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00163	0.00681	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—FGD1—nicotine dependence	0.00163	0.00681	CbGpPWpGaD
Irbesartan—PTGS1—cardiovascular system—nicotine dependence	0.00163	0.0554	CbGeAlD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.0016	0.00667	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—OPRM1—nicotine dependence	0.00155	0.00648	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—TAS2R16—nicotine dependence	0.00148	0.00619	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—FGD1—nicotine dependence	0.00148	0.00619	CbGpPWpGaD
Irbesartan—EDNRA—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00147	0.00615	CbGpPWpGaD
Irbesartan—CYP2C8—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00141	0.00589	CbGpPWpGaD
Irbesartan—AGTR1—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00135	0.00563	CbGpPWpGaD
Irbesartan—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00134	0.00561	CbGpPWpGaD
Irbesartan—CYP2C8—Biological oxidations—CYP2A7—nicotine dependence	0.00133	0.00555	CbGpPWpGaD
Irbesartan—CYP2C8—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00131	0.00547	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—FGD1—nicotine dependence	0.00128	0.00535	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—DRD2—nicotine dependence	0.00123	0.00514	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—OPRM1—nicotine dependence	0.00122	0.00508	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—FGD1—nicotine dependence	0.00116	0.00485	CbGpPWpGaD
Irbesartan—CYP2D6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00116	0.00483	CbGpPWpGaD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00116	0.00482	CbGpPWpGaD
Irbesartan—CYP2C9—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00115	0.00479	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—DRD2—nicotine dependence	0.00112	0.00468	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TAS2R16—nicotine dependence	0.00112	0.00466	CbGpPWpGaD
Irbesartan—CYP2D6—Biological oxidations—CYP2A7—nicotine dependence	0.00109	0.00455	CbGpPWpGaD
Irbesartan—CYP2C9—Biological oxidations—CYP2A7—nicotine dependence	0.00108	0.00451	CbGpPWpGaD
Irbesartan—CYP2D6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00108	0.00449	CbGpPWpGaD
Irbesartan—CYP2C9—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00107	0.00445	CbGpPWpGaD
Irbesartan—CYP2C8—brain—nicotine dependence	0.000983	0.0335	CbGeAlD
Irbesartan—CYP1A2—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000982	0.00409	CbGpPWpGaD
Irbesartan—CYP1A2—Biological oxidations—CYP2A7—nicotine dependence	0.000925	0.00386	CbGpPWpGaD
Irbesartan—CYP1A2—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000913	0.00381	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—DRD2—nicotine dependence	0.000881	0.00367	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—OPRM1—nicotine dependence	0.000878	0.00366	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TAS2R16—nicotine dependence	0.000876	0.00365	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—FGD1—nicotine dependence	0.000876	0.00365	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—WASF2—nicotine dependence	0.000849	0.00354	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—WASF1—nicotine dependence	0.000814	0.00339	CbGpPWpGaD
Irbesartan—PTGS1—brain—nicotine dependence	0.000797	0.0272	CbGeAlD
Irbesartan—EDNRA—Signaling by GPCR—OPRM1—nicotine dependence	0.000797	0.00332	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—AKR1B10—nicotine dependence	0.000774	0.00323	CbGpPWpGaD
Irbesartan—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000758	0.00316	CbGpPWpGaD
Irbesartan—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.000714	0.00298	CbGpPWpGaD
Irbesartan—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000704	0.00294	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—OPRM1—nicotine dependence	0.000689	0.00287	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—FGD1—nicotine dependence	0.000688	0.00287	CbGpPWpGaD
Irbesartan—CYP2D6—brain—nicotine dependence	0.000655	0.0223	CbGeAlD
Irbesartan—JUN—Signaling Pathways—TAS2R16—nicotine dependence	0.000655	0.00273	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—DRD2—nicotine dependence	0.000634	0.00265	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—OPRM1—nicotine dependence	0.000625	0.00261	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—CYP2A7—nicotine dependence	0.000625	0.00261	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—AKR1B10—nicotine dependence	0.000607	0.00253	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—DRD2—nicotine dependence	0.000576	0.0024	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—WASF2—nicotine dependence	0.000545	0.00227	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—WASF1—nicotine dependence	0.000523	0.00218	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—FGD1—nicotine dependence	0.000514	0.00214	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—DRD2—nicotine dependence	0.000498	0.00208	CbGpPWpGaD
Irbesartan—JUN—Immune System—WASF2—nicotine dependence	0.000495	0.00206	CbGpPWpGaD
Irbesartan—JUN—Immune System—WASF1—nicotine dependence	0.000474	0.00198	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—OPRM1—nicotine dependence	0.000471	0.00196	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—AKR1B10—nicotine dependence	0.000454	0.00189	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—DRD2—nicotine dependence	0.000452	0.00189	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—WASF2—nicotine dependence	0.000428	0.00178	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—WASF1—nicotine dependence	0.00041	0.00171	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—OPRM1—nicotine dependence	0.000369	0.00154	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CYP2A7—nicotine dependence	0.000352	0.00147	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—DRD2—nicotine dependence	0.00034	0.00142	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—WASF2—nicotine dependence	0.00032	0.00133	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—WASF1—nicotine dependence	0.000307	0.00128	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—OPRM1—nicotine dependence	0.000276	0.00115	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—DRD2—nicotine dependence	0.000267	0.00111	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CYP2A7—nicotine dependence	0.000228	0.000949	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—DRD2—nicotine dependence	0.0002	0.000832	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP2A7—nicotine dependence	0.000187	0.000779	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP2A7—nicotine dependence	0.000185	0.000772	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP2A7—nicotine dependence	0.000158	0.00066	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP2A7—nicotine dependence	0.000122	0.000509	CbGpPWpGaD
